Product Description
An alpha beta iT cell program targeting CD19 in autoimmune disease and B-cell malignancies. (Sourced from: https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-strengthens-position-autoimmune-disease)
Mechanisms of Action: CAR-T,CD19
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Century Therapeutics
Company Location: PHILADELPHIA PA 19104
Company CEO: Osvaldo Flores
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|